Aequus Pharmaceuticals (TSE:AQS) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Aequus Pharmaceuticals responds to the Canadian shortage of 0.03% bimatoprost, a key glaucoma treatment, by ramping up supply of its preservative-free Zimed® PF eye drops. The company anticipates increased demand and sales revenue for its unique multi-dose product in the wake of this shortage. Aequus is focused on ensuring continuous patient access to this essential medication.
For further insights into TSE:AQS stock, check out TipRanks’ Stock Analysis page.